Mesoblast Ltd (MSB)

1.705
-0.015(-0.87%)
  • Volume:
    1,144,867
  • Bid/Ask:
    1.705/1.710
  • Day's Range:
    1.685 - 1.720

MSB Overview

Prev. Close
1.72
Day's Range
1.685-1.72
Revenue
10.2M
Open
1.72
52 wk Range
1.57-5.7
EPS
-0.22
Volume
1,144,867
Market Cap
1.11B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
3,100,135
P/E Ratio
-
Beta
3.14
1-Year Change
-65.48%
Shares Outstanding
648,083,167
Next Earnings Date
16 Nov 2021
What is your sentiment on Mesoblast Ltd?
or
Market is currently closed. Voting is open during market hours.

Mesoblast Ltd News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong SellSellStrong Sell
SummaryStrong BuyStrong BuyNeutralSellStrong Sell

Mesoblast Ltd Company Profile

Mesoblast Ltd Company Profile

Employees
83
Market
Australia

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company’s products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Read More
  • am new an in I don't understand anything here
    0
    • just buy
      2
      • what is the update for MSB? Buy, Hold or Sell?
        0
        • what is the update for MSB? Buy, Hold or Sell?
          0
          • Watch the sellout tomorrow
            0
            • in my opinion msb will recover quite quickly from current share price. its a lot happening in US including th election. I would be worry if this is the only product they have inline but they have other products which are currently in stage 3 and some will soon be going for fda approval." be greedy when others are fearful " warren buffett
              4
              • It has been a on indicative sell for the lst few weeksAfter that hitThe indicators and MA will promote a further sellThere may be bullish rally due to the fact of how cheap it is since it hasnt dropped this low since 2016But that wont last long as there will be drastic pullback till they prove the product and build investor confident back up
                1
            • in my opinion msb will recover quite quickly from current share price. its a lot happening in US including th election. I would be worry if this is the only product they have inline but they have other products which are currently in stage 3 and some will soon be going for fda approval." be greedy when others are fearful " warren buffett
              2
              • Buy or Sell?
                2
                • if you think they have more ammo in the bank to prove themselves to the FDA - it's shopping time!
                  0
                • Definitely sell, the sentiment is bearish. The share price will not bounce in the foreseeable future unless treatment efficacy is further substantiated & FDA approval is granted. There is a long way to go before this happens.
                  0
                • George SalmaStotally agree, thats what i said. Absolute gamble if you buy, youre more likely to win against the casino than to make money on this share. A buy would be around the march low, $1 something
                  0
              • overpriced in my opinion
                4
                • based on what just happened. it dropped due to FDA not being in favour. time to buy very soon. price drop for some yum yum
                  0
                • based on what just happened. it dropped due to FDA not being in favour. time to buy very soon. price drop for some yum yum
                  0
                • tu nguyena buy at its march low is a buy for a quick buck
                  0
              • Reaults are coming out anytime now. Straps yourself gentlemen. Time for take off.
                1
                • wow.. this for great potential!
                  2
                  • one to watch. steady climber
                    2
                    • one to watch. steady climber
                      1
                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.